{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:27:05Z","timestamp":1790202425072,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.hlc.2025.05.092","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T09:57:21Z","timestamp":1762595841000},"page":"1319-1331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Modernising Acute PE and VTE Management: Meta-Analysis of Newer Anticoagulants Versus Traditional Therapy on Recurrence and Mortality"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5713-431X","authenticated-orcid":false,"given":"Udvass Kumar","family":"Kotokey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savitri","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2025.05.092_bib1","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/ATVBAHA.114.304488","article-title":"Thrombosis: a major contributor to global disease burden","volume":"34","author":"Raskob","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.hlc.2025.05.092_bib2","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis: epidemiologic aspects","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.hlc.2025.05.092_bib3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/eurheartj\/ehz236","article-title":"Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany","volume":"41","author":"Keller","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2025.05.092_bib4","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hlc.2025.05.092_bib5","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","article-title":"Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation","volume":"115","author":"Hylek","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2025.05.092_bib6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.05.092_bib7","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.05.092_bib8","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hlc.2025.05.092_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/qhc.12.1.18","article-title":"Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project","volume":"12","year":"2003","journal-title":"Qual Saf Health Care"},{"key":"10.1016\/j.hlc.2025.05.092_bib10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fmed.2017.00142","article-title":"Cancer-associated venous thromboembolism: a practical review beyond low-molecular-weight heparins","volume":"4","author":"Smrke","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.hlc.2025.05.092_bib11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/rth2.12002","article-title":"Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis","volume":"1","author":"Khorana","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.hlc.2025.05.092_bib12","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1111\/j.1538-7836.2006.02073.x","article-title":"Barriers to the long-term use of low-molecular weight heparins for treatment of cancer-associated thrombosis","volume":"4","author":"Wittkowsky","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.hlc.2025.05.092_bib13","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.hlc.2025.05.092_bib14","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Hokusai-VTE Investigators","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.05.092_bib15","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral Rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"EINSTEIN Investigators","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.05.092_bib16","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"EINSTEIN\u2013PE Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.05.092_bib17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.05.092_bib18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.05.092_bib19","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.05.092_bib20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1378\/chest.14-0402","article-title":"Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis","volume":"147","author":"Vedovati","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.hlc.2025.05.092_bib21","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.hlc.2025.05.092_bib22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hlc.2025.05.092_bib23","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1055\/s-0040-1712098","article-title":"Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis","volume":"120","author":"Giustozzi","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hlc.2025.05.092_bib24","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/1060028020960037","article-title":"Direct oral anticoagulant for the treatment of VTE in cancer patients: a systematic review and meta-analysis","volume":"55","author":"Dong","year":"2021","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.hlc.2025.05.092_bib25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/1078155217718382","article-title":"Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: the Re-CLOT study","volume":"24","author":"Alzghari","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.hlc.2025.05.092_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1078155217690922","article-title":"Recurrence of malignancy-associated venous thromboembolism among patients treated with Rivaroxaban compared to enoxaparin","volume":"24","author":"Nicklaus","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.hlc.2025.05.092_bib27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2016.12.016","article-title":"Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: a retrospective analysis","volume":"150","author":"Ross","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.hlc.2025.05.092_bib28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1078155217730129","article-title":"Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants","volume":"25","author":"Uppuluri","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.hlc.2025.05.092_bib29","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis","volume":"12","author":"van der Hulle","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.hlc.2025.05.092_bib30","article-title":"Oral direct thrombin inhibitors or oral factor xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism","volume":"4","author":"Li","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.hlc.2025.05.092_bib31","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2025.05.092_bib32","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hlc.2025.05.092_bib33","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/jth.15153","article-title":"Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs","volume":"19","author":"Schaefer","year":"2021","journal-title":"J Thromb Haemost"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950625004573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950625004573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T15:27:44Z","timestamp":1766590064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950625004573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1443950625004573"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2025.05.092","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modernising Acute PE and VTE Management: Meta-Analysis of Newer Anticoagulants Versus Traditional Therapy on Recurrence and Mortality","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2025.05.092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}